Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Advertisement

Advertisement




May
30
Today In Oncology
After the Founder: What a Cervical Cancer Program in Haiti Teaches About Sustaining Prevention
Pain and Health-Related QOL With Darolutamide in Metastatic Hormone-Sensitive Prostate Cancer
Lymph Node Surgery and CDK4/6 Inhibitor Treatment in Early Breast Cancer
ASCO Collaborates With Ryght AI to Accelerate Site Selection for Metastatic Breast Cancer Trial
Behind the Scenes of the 2026 ASCO Annual Meeting
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo